- Fecal Incontinence
This CME Monograph will target gastroenterologists and other healthcare providers involved in the care of patients with irritable bowel syndrome (IBS).
Upon completion of this activity, participants should be better able to:
Describe approaches for assessing study design and safety, efficacy, and tolerability results for IBS/CIC therapies
Integrate data from randomized controlled trials (RCTs) with clinical experience to design evidence-based treatment plans for patients with IBS-C/CIC
Integrate data from RCTs with clinical experience to design evidence-based treatment plans for patients with IBS-D
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Gi Health Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: February 1, 2017Expiration Date: February 1, 2018 EXPIRED
Disclosure of Conflicts of Interest
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All staff at the Annenberg Center of Health Sciences at the Eisenhower and the Gi Health Foundation (GIHF) have no relationships to disclose.
Learner Assurance Statement
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as the result of prospective faculty member's significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those faculty with financial interests that can be reconciled with the goals and education integrity of the CME activity.
Additional Planners/Reviewers Affiliation and Disclosure Statements:
William D. Chey, MD, AGAF, FACG, FACP Consultant/Research Support: Ardelyx, Ironwood Pharmaceuticals, Inc., Vibrant Consultant: Allergan, Inc., Ardelyx, IMHealthScience, Ironwood Pharmaceuticals, Inc., Prometheus, QOL Medical Salix/Valeant Pharmaceuticals, Vibrant Honorarium Recipient: Ardelyx, IMHealthScience, Ironwood Pharmaceuticals, Inc., Prometheus, QOL Medical Salix/Valeant Pharmaceuticals Other Financial Material Support: CMO, My Total Health
Barb Forney, CME Compliance – No Relevant Relationships Julie Messick, PharmD, Medical Writer – No Relevant Relationships
This monograph is based on presentations by Darren M. Brenner, MD, Brooks D. Cash, MD, William D. Chey, MD, Brian E. Lacy, MD, Mark Pimentel, MD, and Philip S. Schoenfeld, MD, given at the 2016 ACG Clinical Symposium, "An Evidenced-Based Approach to IBS and CIC Applying New Advances to Daily Practice." Dr Chey was the lead faculty and reviewed the monograph.
Supported by educational grants from Allergan, Inc., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, and Synergy Pharmaceuticals.